Back to Search
Start Over
CD22 TCR-Engineered T Cells Exert Anti-Leukemia Cytotoxicity without Causing Inflammatory Responses
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2085-2085, 1p
- Publication Year :
- 2023
-
Abstract
- Chimeric antigen receptor (CAR) T cells are remarkably effective, especially against B-cell malignancies. However, CAR-T cell therapy is also associated with cytokine-driven inflammatory toxicities such as cytokine release syndrome. Similar cytokine-related toxicity can occur after bispecific T-cell engager (BiTE) administration. It is unknown whether these inflammatory responses are specifically related to T-cell-mediated therapies that are activated through artificial CAR or BiTE signals.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64700495
- Full Text :
- https://doi.org/10.1182/blood-2023-187314